Now Reading: Sun Pharma gets USFDA nod for ILUMYA to treat psoriatic arthritis
-
01
Sun Pharma gets USFDA nod for ILUMYA to treat psoriatic arthritis
Sun Pharma gets USFDA nod for ILUMYA to treat psoriatic arthritis
The Story in Brief
Sun Pharmaceutical Industries on Friday, 30 October 2026, said the US Food and Drug Administration had approved its drug ILUMYA (tildrakizumab-asmn) for treating adults with active psoriatic arthritis. The approval expands the drug's use beyond moderate-to-severe plaque psoriasis, for which it was approved in the US in 2018. ILUMYA is an interleukin-23 inhibitor administered exclusively by healthcare professionals.
The approval is backed by data from two Phase 3 trials, INSPIRE-1 and INSPIRE-2, which assessed the drug after two doses at 24 weeks. The company stated that safety findings were consistent with ILUMYA's established profile and no new safety signals were identified. The drug may increase the risk of infections, and patients must be evaluated for tuberculosis before starting treatment. The most common adverse reactions reported were upper respiratory tract infections and Covid-19.
Sun Pharma estimates about 2.4 million people in the US live with psoriatic arthritis, a chronic immune-related condition causing joint pain, swelling and stiffness. Rick Ascroft, North America CEO, said the approval 'builds on the established clinical experience of ILUMYA in plaque psoriasis'. The stock closed at Rs 1,762.95 on Thursday, up 0.28% from the previous close.
Indian Opinion Analysis
Business Standard leads with the regulatory approval and the drug's mechanism of action, including Phase 3 trial details and a quote from Sun Pharma's North America CEO, and omits any stock price data. Business Today leads with the stock price movement from the previous day and includes a quote from the same CEO but adds a standard disclaimer about investment advice. The two outlets present the same factual event, the FDA approval of ILUMYA for psoriatic arthritis, but Business Standard emphasises the clinical and regulatory significance, while Business Today frames it as a stock market event. Neither source criticises the government or Sun Pharma, and both report the same Phase 3 data and safety warnings. Uniform straight reporting of a corporate announcement, the sole difference is the chosen lead: the news itself versus the market reaction the following day.
Coverage: 2 sources, 2 neutral
Sources (2): business-standard.com (neutral report), businesstoday.in (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.
